Merck's Remigromig Meets Goal in DME Trial, Raises Safety Concerns
Merck's experimental eye drug remigromig met the non-inferiority goal in a diabetic macular edema trial, though the results also raised safety concerns.
2newsrooms
2articles
18 hoursrunning
Oct 10first seen
Ask Scout
Scout answers questions about this story using only the coverage below.
Coverage over time
Articles
| Oct 11, 9:42 AM | seekingalpha.com | Merck's experimental eye drug meets goal in trial, but raises safety concerns |
| Oct 10, 3:16 PM | investing.com | Merck’s remigromig meets non-inferiority goal in DME trial |